Cell & Gene Therapies

© Getty Images

Insmed unveils new research platforms and capabilities

By Isabel Cameron

US biopharma Insmed has announced progress across its early-stage research programs at the company's investor and analyst event, The Future of Rare at Insmed: Functional Genes, AI-Enhanced Proteins, Glowing Algae, and More.

BioMarin opens €38m expansion at Irish manufacturing site

BioMarin opens €38m expansion at Irish manufacturing site

By Rachel Arthur

BioMarin Pharmaceutical has opened the expansion of its manufacturing plant at Shanbally, Co. Cork: with the site now able to provide end-to-end manufacturing for a number of the company’s commercial products.

Pic:getty/stocktrekimages

bluebird bio submits BLA for sickle cell disease gene therapy

By Rachel Arthur

bluebird bio has announced the submission of a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for lovotibeglogene autotemcel (lovo-cel) gene therapy in patients with sickle cell disease (SCD).

A Meissner lab. Pic: Meissner

Meissner to build new $250m manufacturing facility in Athens, Georgia

By Rachel Arthur

Meissner Corporation – a company which manufactures advanced microfiltration and therapeutic manufacturing systems for pharmaceutical drugs, therapeutics, biologics, and cell and gene therapies - will invest nearly $250m in a new manufacturing facility...

Pic:getty/davidlees

Sartorius to acquire Polyplus

By Rachel Arthur

Life science group Sartorius will acquire French company Polyplus for around €2.4bn ($2.6bn).

© GettyImages/ipopba

Urgent action needed to reduce high costs of gene therapies

By Jane Byrne

The extremely high costs of gene therapies are unsustainable, and a global commitment to affordable, equitable access to these treatments is urgently needed, concluded the organising committee of a conference on human genome editing.

Pic:getty/antoniosolano

Syena sets out to pioneer TCR NK cell therapy

By Rachel Arthur

New company Syena says it has the potential to create the next generation of cell therapy: combining the safety, potency and scalability of natural killer (NK) cells with the ability of T cell receptors (TCR) to target intracellular tumor antigens.

© GettyImages/Ca-ssis

Lonza: Robust industry fundamentals are supportive of growth

By Jane Byrne

Despite an uncertain macroeconomic environment, Lonza says its ‘resilient’ business model and sustained market demand delivered a strong financial performance in 2022, in line with the Swizterland based CDMO’s outlook.

© GettyImages/AlexanderFord

Opus acquires two compounds for inherited retinal diseases

By Jane Byrne

Last week saw Opus Genetics announce it had acquired the rights to two preclinical-stage adeno-associated virus (AAV)-based gene therapy product candidates for inherited retinal diseases (IRDs) from Iveric Bio.

Follow us

Webinars